Actively Recruiting
Registry to Monitor Long-term Safety and Effectiveness of Odevixibat Bylvay in People With Progressive Familial Intrahepatic Cholestasis PFIC in China
Led by Ipsen · Updated on 2026-10-23
20
Participants Needed
6
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This observational study collects information from people in China with Progressive Familial Intrahepatic Cholestasis PFIC, a rare genetic liver disease that affects bile flow and can cause severe itching. The study focuses on individuals who take odevixibat Bylvay as part of their routine clinical care. Odevixibat has been approved to treat itching caused by PFIC in babies 6 months and older in China, following approvals by regulatory agencies in Europe and the United States. Participants in this registry are those diagnosed with PFIC who have been prescribed odevixibat by their doctors. The study observes these participants while they are on active treatment with odevixibat, including those with treatment interruptions. The registry aims to assess long-term safety by tracking adverse events and to describe how effective the treatment is over time. During the study, participants are monitored for about five years starting from their consent. Researchers will collect data on adverse events, serious adverse events, survival without surgery or liver transplant, itching improvement, and changes in blood bile acid levels. This long-term follow-up helps understand the real-world outcomes of odevixibat treatment in PFIC patients under routine care.
CONDITIONS
Brief Title
A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in China
Research Team
I
Ipsen Clinical Study Enquiries
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here